DVC1 0101

Drug Profile

DVC1 0101

Alternative Names: DVC1-0101; Fibroblast growth factor 2 gene therapy - ID Pharma; SeV-10101; SEV1-0101

Latest Information Update: 15 Jun 2016

Price : $50

At a glance

  • Originator DNAVEC Corporation
  • Developer ID Pharma; Kyushu University
  • Class Gene therapies; Nucleic acids
  • Mechanism of Action Angiogenesis inducing agents; Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Peripheral ischaemia

Most Recent Events

  • 08 Jun 2016 ID Pharma plans a phase I/IIa trial for Intermittent claudication and Peripheral ischaemia in Australia (IM) (ACTRN12615001144505)
  • 15 Dec 2015 Clinical development for Peripheral ischaemia is ongoing in Japan
  • 11 Aug 2005 SeV1 0101 is available for licensing in US, Europe and Japan (http://www.dnavec-corp.com/)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top